Business
Bipartisan battle over prescription intermediaries heats up on September 28, 2023 at 10:00 am Business News | The Hill

The intermediaries in the prescription drug supply chain are stuck between a rock and a hard place, facing congressional scrutiny and pharmaceutical-industry-backed efforts to reform the multibillion-dollar industry.
Pharmacy benefit managers (PBMs) have emerged as a bipartisan target in a divided Congress.
Members across the aisle have introduced at least a dozen bills so far this year that would address the impact of increasing consolidation among PBMs and lack of transparency into prescription drug access and pricing.
“It’s just absolutely maddening and I think we have an area here … where we can actually work together and have some bipartisanship I dare say,” said Rep. Stephen Lynch (D-Mass) during a recent House Oversight Committee hearing on PBMs.
The three biggest PBMs — which control roughly 80 percent of the market — are CVS Health’s CVS Caremark, Cigna’s Express Scripts and UnitedHealthcare’s Optum.
Each of these PBMs is owned by parent companies that also own health insurers. Consolidation and the vertical integration of PBMs into health care companies is a high priority for the lawmakers championing these reforms.
“When PBMs negotiate with a pharmacy or a health insurer, they are either negotiating with themselves or one of their direct competitors. This can create incentives to do things that have negative impacts on patients,” Rep. James Comer (R-Ky.), chairman of the Oversight Committee, said during the recent hearing.
What does a PBM do?
PBMs operate in the middle of the drug supply chain and develop formularies, the list of drugs that insurance providers will cover. By leveraging their influence over what medicines are covered, PBMs negotiate rebates and discounts from manufacturers.
These companies also contract with pharmacies to reimburse them for drugs that are dispensed. One tactic that has garnered particular criticism is the practice of spread pricing, when PBMs receive a reimbursement from health plans that’s higher than what they pay to pharmacies, keeping the difference.
“At some point, they recognized that they could actually control what drugs are preferred or not preferred based on their central position in working with the insurance industry,” said Robert Levin, president of the Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition aimed at addressing PBM practices.
“By creating preferred drugs, they could then create a system of ‘How do you get to be on that preferred, top tier list?’ And the obvious way for them was to extract money from the manufacturers in trade for their ability to access the insurance market.”
How lawmakers are taking action
The House Oversight and Accountability Committee held its second hearing on PBMs last week, during which members on both sides of the aisle demonstrated their shared resolve for PBM reform.
Lawmakers on the panel took a critical eye toward PBM practices, both in how patients are impacted and what effect they have on the market.
Rep. Pete Sessions (R-Texas) said he believed the three major PBM giants engaged in “anti-competitive behavior, which should be against the federal law.”
The Pharmacy Benefit Manager Transparency Act, introduced in January by Sens. Maria Cantwell (D-Wash.) and Chuck Grassley (R-Iowa), has been a top target for industry lobbyists rooting for and against the bill.
The bill would bar PBMs from engaging in what it refers to as “deceptive” practices, such as charging an insurer more than what the PBM reimburses a pharmacy. The Senate Committee on Commerce, Science and Transportation approved the legislation in March, and it hasn’t moved since.
If enacted, the bill would reduce the federal deficit by $740 million over the next 10 years, the Congressional Budget Office estimated.
The Modernizing and Ensuring PBM Accountability (MEPA) Act was approved by the Senate Finance Committee in July. According to a Finance Committee aide, a version based on the chairman’s mark could be introduced as early as this week.
Outside of Congress, the Federal Trade Commission (FTC) is conducting an inquiry into PBMs and their impact on prescription drug access. In July, the FTC issued a statement cautioning against reliance on prior materials from the agency that opposed PBM transparency requirements.
The FTC said those older statements and studies “no longer reflect current market realities.”
The lobbying battle over PBM reform
This mounting attention on PBMs has spurred a massive PR campaign to sway public perception both for and against the industry.
The national trade association representing PBMs is spending more money than ever on federal lobbying and hired two new lobbying firms this summer to advocate for the industry.
The Pharmaceutical Care Management Association (PCMA) spent $6.2 million on federal lobbying in the first half of 2023, on pace to blow past the $8.7 million it spent on federal lobbying in all of 2022, according to disclosures analyzed by the money-in-politics research group OpenSecrets.
The PCMA spent $3.4 million in the second quarter alone, the most it’s ever spent on federal lobbying in a single quarter.
The PCMA did not return requests for comment from The Hill. In a statement issued Monday in response to the Oversight hearing, the group sought to refocus the blame for high drug prices back onto manufacturers.
“Fierce competition in the generic market is what drives down prices,” the PCMA said.
During last week’s hearing, Dr. Rena Conti, a health care economist and associate professor in the Questrom School of Business at Boston University, also pointed out that “Drug prices are set high in the United States because, simply, drug manufacturers can charge them, and we will pay them.”
Why drugmakers are fighting back
The influential trade association representing those manufacturers, Pharmaceutical Research and Manufacturers of America (PhRMA), has been doggedly going after PBMs.
PhRMA is consistently among the top five organizations spending the most money on federal lobbying, and it spent $14.5 million in the first six months of 2023 lobbying on a range of issues, including the Pharmacy Benefit Manager Transparency Act.
The pharmaceutical industry is itself navigating a changing landscape as the Centers for Medicare & Medicaid Services moves to negotiate drug prices as directed by the Inflation Reduction Act (IRA). The landmark legislation signed into law by President Biden last fall included provisions to lower prescription drug prices.
Lobbyists cited the IRA more on federal lobbying disclosures than any other bill last year, with PhRMA at the front of the pack, according to disclosures analyzed by OpenSecrets.
“If you look at the IRA, not only did it give government bureaucrats a lot of power to make political decisions over what medicines people can get now and in the future, it did nothing to address the abuses in the PBM market that we’re talking about today,” Nick McGee, deputy vice president of public affairs at PhRMA, told The Hill in a phone interview.
The passage of the IRA was a huge blow to PhRMA, which has gone through its in-house lobbying transitions over the past year. Last week, the industry group named Steve Tilton, the top lobbyist at Takeda and a former two-time PhRMA vice president, as its new senior vice president of federal advocacy.
“We can’t address the issues of patient affordability if we’re not addressing the abuses in the PBM system, and so that’s going to continue to be a priority for us,” McGee said.
PBMs face fire from doctors, AARP
It’s not just the pharmaceutical industry going after PBMs.
The AARP, which supported the IRA drug price provisions opposed by PhRMA, has also backed several PBM reform bills. In August, the organization sent letters endorsing the PBM Transparency Act, Modernizing and Ensuring PBM Accountability Act and Patients Before Middleman (PBM) Act.
“Lowering drug prices cannot be done in a vacuum. As AARP continues the fight to hold drug companies accountable for price gouging older Americans, we also support bipartisan efforts that work to correct behavior in the entire prescription drug supply chain,” Bill Sweeney, AARP senior vice president for government affairs, told The Hill in a written statement.
“The PBM Transparency Act, as well as other pending drug price reform bills, will help lower costs for consumers,” he said.
The American Medical Association also sent a letter to Cantwell and Grassley in March supporting the PBM Transparency Act and the Prescription Pricing for the People Act.
The American Pharmacists Association, National Association of Manufacturers and a host of other organizations and public figures have voiced support for some congressional PBM reforms.
Physicians say the presence of PBMs threatens the “sanctity” of the doctor-patient relationship.
“The PBMs, I just don’t see them producing anything. They only produce red tape and bureaucracy,” said Levin from ATAP told The Hill.
Levin, who has practiced medicine for 35 years, can recall what the health care space was like before PBMs became commonplace and says their growth has been accompanied by “more frustration, more obstacles, roadblocks.”
Health Care, Business, Lobbying The intermediaries in the prescription drug supply chain are stuck between a rock and a hard place, facing congressional scrutiny and pharmaceutical-industry-backed efforts to reform the multibillion-dollar industry. Pharmacy benefit managers (PBMs) have emerged as a bipartisan target in a divided Congress. Members across the aisle have introduced at least a dozen bills so far…
Business
Building a 10 Million Army: One Leader’s Mission to Save Tomorrow

Sustainability is often spoken about as if it belongs only to scientists, policy experts, or environmental activists. On the Roselyn Omaka Show, Otto Cannon makes the case that it belongs to everyone. His message is both urgent and deeply human: sustainability is not just about the environment, but about creating a world where people, planet, and profit exist in balance.
Cannon’s mission is striking in its scale. He wants to build what he calls a global army of 10 million sustainability leaders—people across industries and communities who choose to think beyond short-term gains and take responsibility for the future they are helping shape.
My biggest mission is to raise a 10 million global army of sustainability leaders.
Otto’s understanding of this work did not begin in a conference room. It began in childhood, shaped by a father who taught him to see the world’s problems as personal assignments. That early influence instilled in him the belief that real leadership means stepping forward, identifying what is broken, and dedicating yourself to fixing it.

That mindset later became deeply personal. In one of the interview’s most emotional moments, Cannon shares how the death of his dog after swallowing a plastic bottle cap changed his life. What might have seemed like an isolated tragedy became, for him, a doorway into a much larger truth: waste is never just waste when it destroys ecosystems, harms wildlife, and threatens the future.
Instead of turning away, he turned pain into action. Through his work, he helped build a recycling company that processed over 10,000 tons of plastic and supported tree-planting efforts that have already reached more than 500,000 trees. His story reflects the broader idea of sustainability leadership, which is commonly framed as the integration of environmental, social, and economic responsibility into real-world decision-making.
What makes Cannon’s perspective especially compelling is the way he challenges common misconceptions. He argues that sustainability is too often boxed into environmental language alone, when in reality it applies to every sector—fashion, construction, energy, transportation, manufacturing, and beyond. This broader understanding aligns with current sustainability leadership thinking, which emphasizes systems, collaboration, and long-term value creation across sectors.
Profit should never come at the expense of people or the planet.
That belief is central to everything Cannon describes. For him, sustainability is not anti-business. It is about designing business, innovation, and progress in a way that does not leave harm behind for future generations. A solution that helps today but creates a deeper problem tomorrow, he argues, is not truly a solution at all.

This is also the thinking behind the Global Sustainability Summit and Awards in London, where Cannon brings together leaders from government, business, and civil society to share ideas, showcase innovation, and inspire action. Cross-sector collaboration is widely recognized as a core part of effective sustainability work, especially when the goal is cultural and systemic change rather than isolated projects.
The power of Cannon’s message lies in its accessibility. He is not calling only on policymakers or executives. He is speaking to creators, founders, farmers, designers, builders, and everyday professionals—anyone who has influence over materials, waste, systems, sourcing, or the choices that shape modern life.
By the end of the conversation, one image lingers: the idea that one person is a drop of water, but many drops together can become a wave. That is the future Otto Cannon is working toward—not a movement powered by one voice, but one built by millions who decide that sustainability is not optional, but necessary.
Business
GLOBAL SUSTAINABILITY SUMMIT RETURNS FOR ITS 5TH EDITION AT THE BRITISH PARLIAMENT – HOUSE OF LORDS, PALACE OF WESTMINSTER

FOR IMMEDIATE RELEASE
Theme: “People, Planet, and Profit in the Age of AI and Innovation”
London, United Kingdom — The Global Sustainability Summit (GSS) is officially back for its landmark 5th Edition, continuing its legacy as one of the leading international platforms driving sustainable development, climate action, ethical investment, innovation, and global collaboration.

Convened annually at the prestigious British Parliament, House of Lords, Palace of Westminster, by Ambassador Canon Chinenem Otto, the Summit has, over the last four years, successfully fostered international dialogue and partnerships that have contributed to the advancement of global sustainability goals, the establishment of sustainability-focused ministries, departments and policy structures across national and subnational governments, and the attraction of major investors into sustainable development projects, corporations and emerging economies.
This year’s summit, themed “People, Planet, and Profit in the Age of AI and Innovation,” will explore how emerging technologies, responsible leadership, sustainable finance, innovation, and global partnerships can shape a more inclusive, resilient and environmentally conscious future.

The 5th Edition promises to be the most impactful yet, bringing together world leaders, policymakers, diplomats, investors, academics, innovators, climate experts and youth leaders from across the globe to discuss actionable solutions toward achieving a sustainable and equitable future.
Among the distinguished speakers, delegates and honorees already lined up for the Summit are:
• His Excellency Mallam AbdulRahman AbdulRazaq — Executive Governor of Kwara State, Nigeria and Chairman of the Nigeria Governors’ Forum
• His Excellency Senator Prince Bassey Otu — Executive Governor of Cross River State, Nigeria
• Ambassador Patricia Espinosa Cantellano — Former Executive Secretary of UN Climate Change (UNFCCC) and Former Foreign Minister of Mexico

• Lord Marvin Rees, Baron Rees of Easton OBE — Member of the House of Lords, United Kingdom
• Hon. Neema K. Lugangira — Secretary-General of Women Political Leaders (WPL), Brussels and Former Member of Parliament
• Her Excellency Dr. Netumbo Nandi-Ndaitwah — President of the Republic of Namibia
• His Excellency Nangolo Mbumba — Former President of Namibia
• Former President of Tanzania
• Her Excellency Ambassador Professor Olufolake AbdulRazaq — First Lady of Kwara State, Nigeria and Chairperson of Nigeria Governors’ Spouses Forum
• Your Excellency Dr. Dikko Umar Radda, PhD, CON — Executive Governor of Katsina State and Chairman of the Northwest Governors Forum, Nigeria
• Hon. Sam Shafiishuna Nujoma — Governor of Khomas Region, Namibia

• H.E. Mr. Veiccoh Nghiwete — High Commissioner of the Republic of Namibia to the United Kingdom
• Her Excellency Ms. Macenje “Che Che” Mazoka — High Commissioner of Zambia to the United Kingdom
• Ms. Danielle Newman — Partner Lead, ICT, World Economic Forum
• Leanne Elliott Young — Co-founder, Institute of Digital Fashion & CommuneEast
• Ms. Chloe Russell — Producer & Presenter, Art, Science and Nature
• Professor Marie-Claire Cordonier Segger — University of Cambridge & University of Waterloo
• Dr. Alexandra R. Harrington — IUCN World Commission on Environmental Law (WCEL)
• Professor Payam Akhavan — Massey College, University of Toronto
• Mr. Mallai C. E. Sathya — President, Dravida Vetri Kazhagam and International Movement for Tamil Culture Asia

The Summit will feature high-level panel discussions, strategic investment conversations, sustainability awards, policy dialogues, innovation showcases, youth engagement sessions and international networking opportunities focused on climate resilience, ethical financing, food-water-energy sustainability, circular economy, artificial intelligence, diplomacy and sustainable development.
Speaking ahead of the Summit, Convener Ambassador Canon Chinenem Otto noted:
“As the world rapidly evolves through artificial intelligence and technological innovation, we must ensure that sustainability remains people-centered, environmentally responsible and economically inclusive. The Global Sustainability Summit continues to serve as a bridge connecting governments, institutions, innovators and investors to accelerate practical sustainability solutions globally. Our fifth edition is not only a celebration of progress made over the years, but also a renewed call for global collaboration and actionable impact toward achieving the Sustainable Development Goals and Net Zero ambitions.”
The Global Sustainability Summit continues to position itself as a catalyst for transformative partnerships and sustainable global progress, reinforcing the urgent need for collective action toward a more resilient and sustainable future.
More announcements regarding additional speakers, partners and summit activities will be unveiled in the coming weeks.
Business
What the Michael Biopic Means for Every Indie Filmmaker

The Michael Jackson biopic Michael is more than celebrity drama; it is a real-time lesson in how legal decisions can quietly rewrite a story that millions of people will see. You do not need a $200M budget for the same forces—contracts, settlements, and rights issues—to shape or even erase key parts of your own work.

What Happened to Michael
The film Michael originally included a third act that addressed the 1993 child sexual abuse allegations and their impact on Jackson’s life and career. Trade reports say this version showed investigators at Neverland Ranch and dramatized the scandal as a turning point in the story. After cameras rolled, lawyers for the Jackson estate realized there was a clause in the settlement with accuser Jordan Chandler that barred any depiction or mention of him in a movie.
Because of that old agreement, the filmmakers had to remove all references to Chandler and rework the ending so the story stopped years earlier, in the late 1980s at Jackson’s commercial peak.
According to reporting, this meant roughly 22 days of reshoots, costing around 10–15 million dollars and pushing the total budget over 200 million.
Meanwhile, actress Kat Graham confirmed her portrayal of Diana Ross was cut for “legal considerations,” showing how likeness and approval issues can wipe out an entire character even after filming.
For audiences, the result is a movie that intentionally avoids one of the most controversial chapters of Jackson’s life, which some critics argue makes the portrait feel incomplete or selectively curated.
The Hidden Power of Contracts and Rights
The key detail in the Michael story is that a contract signed decades ago could dictate what present-day filmmakers are allowed to show. That settlement clause did not just affect the people who signed it; it effectively controlled the narrative of a big-budget film made years later. This is how legal documents become invisible co-authors: they quietly set boundaries around what your story can and cannot include.
Creators face similar invisible lines with:
- Life-rights and defamation: If you dramatize real people, especially in a negative light, they can claim defamation or invasion of privacy if your portrayal is inaccurate or harmful.
- Copyright and trademarks: Unlicensed music, clips, logos, or artwork can trigger copyright or trademark claims that block distribution or force expensive changes.
- Distribution contracts: Some deals give distributors the right to re-edit, retitle, or repackage your work without your approval unless you negotiate otherwise.
Legal commentary warns that fictionalizing real events and people carries heightened risk because audiences tend to connect your dramatization back to actual individuals. That risk does not disappear just because you are “small” or “indie”; impact, not audience size, usually determines exposure.
Why This Matters for Indie Filmmakers and Creators
Independent filmmakers often choose the indie route precisely to maintain creative control, but they can face more risk if they skip legal planning. Common problems include unclear ownership of the script, missing music licenses, handshake agreements with collaborators, and no written permission to use locations or people’s likenesses. These are the kinds of issues that can derail distribution, block a streaming deal, or force last-minute cuts that fundamentally change your story.
Legal guides for indie filmmakers consistently emphasize a few realities:
- You do not fully “own” your film unless you have clear contracts for writing, directing, producing, and underlying rights.
- Unregistered or unlicensed creative elements (like music and logos) can make your project uninsurable or unattractive to distributors.
- Fixing legal problems after the fact is almost always more expensive and limiting than planning for them at the beginning.
So when you watch Michael skip over certain events, you are seeing, in exaggerated form, the same forces that can shape an indie short, web series, documentary, or podcast episode.
Practical Legal Lessons You Can Apply Now
You do not need a law degree, but you do need a basic legal strategy for your creative work. Here are practical steps drawn from entertainment-law and indie-film resources:
- Clarify who owns the story
- Use written agreements with co-writers, directors, and producers that state who owns the script and finished film.
- If your work is based on a real person or memoir, secure life-rights or written permission where appropriate, especially if the portrayal is sensitive.
- Be intentional with real people and events
- When telling true or inspired-by-true stories, avoid making specific, negative claims about identifiable people unless they are well-documented and legally vetted.
- Change names, details, and circumstances enough that the person is not clearly identifiable if you do not have their cooperation.
- Lock down music and visuals
- Use original scores, licensed tracks, or reputable libraries; never assume you can keep a song just because it is in a rough cut.
- Clear artwork, logos, and recognizable brands, or replace them with generic or custom-designed alternatives.
- Protect yourself in contracts
- When signing any distribution or platform deal, read the clauses about editing, retitling, and marketing carefully; ask for limits or at least consultation rights.
- Include terms that let you reclaim rights if a partner fails to release the work, goes dark, or breaches key promises.
- Document everything
- Keep organized copies of releases, licenses, and contracts; these documents are part of your project’s value and proof of your rights.
- Register your work where applicable (for example, copyright), which strengthens your ability to enforce your rights if someone copies you.
Education-focused legal resources repeatedly stress that preventative steps—basic contracts, clear permissions, and simple registrations—are far cheaper than dealing with takedowns, lawsuits, or forced rewrites later.
The Big Takeaway: Story and Law Are Connected
The Michael biopic illustrates what happens when legal obligations and creative vision collide: whole characters disappear, endings are rewritten, and the public only sees a version of the story that fits within old contracts.
As an indie filmmaker, writer, or content creator, you may not have millions at stake, but you do have something just as valuable—your voice and your ability to tell the story you meant to tell.
Understanding the legal dimensions of your work is not a distraction from creativity; it is a way of protecting it. When you know where the legal boundaries are, you can design stories that are bold, truthful, and still safe enough to reach the audiences they deserve.
Advice5 days agoHow to Make Your Indie Film Pay Off Without Losing Half to Distributors
Advice5 days agoHow to Find Your Voice as a Filmmaker
News4 weeks agoFIPRM Expands Into Sports, Partners With Bolanle Media to Launch New Media Platform
Business2 weeks agoWhat the Michael Biopic Means for Every Indie Filmmaker
Entertainment4 weeks agoMother’s Day AfroFun Praise Party: Gospel Dance, Fitness & Feel‑Good Stats in 60 Minutes
Business1 week agoGLOBAL SUSTAINABILITY SUMMIT RETURNS FOR ITS 5TH EDITION AT THE BRITISH PARLIAMENT – HOUSE OF LORDS, PALACE OF WESTMINSTER
News4 days agoCan AI Really Steal Your Fingerprints From a Selfie?
Film Industry3 days agoActors Win AI Deal – But Your Face Is Still Training the Machine


















